E-ISSN: 1305-9327 ISSN: 1305-9319
HER-2 Mutations in Non-Small Cell Lung Cancer
PDF
Cite
Share
Request
Review
VOLUME: 14 ISSUE: 3
P: 322-325
September 2018

HER-2 Mutations in Non-Small Cell Lung Cancer

Med J Bakirkoy 2018;14(3):322-325
DOI: 10.5350/BTDMJB.20170418063202
Erdem Sen 1
Guler Yavas 2
Ozlem Ata 2
1. Selcuk University, Department of Medical Oncology, Konya, Turkey
2. Selcuk University, Department of Radiation Oncology, Konya, Turkey
No information available.
No information available
Received Date: 18.04.2017
Accepted Date: 01.11.2017
PDF
Cite
Share
Request

ABSTRACT

Lung cancer is a heterogeneous and complex disease. Oncogenic driver mutations are critical for lung cancer development and serve as therapeutic targets. Oncogenic driver mutations are well defined in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) and reactive oxygen species-1 (ROS-1) mutations. Human epidermal growth factor receptor-2 (HER-2) positivity and anti-HER-2 treatments are well studied in breast cancer. In non-small cell lung cancer (NSCLC), these treatment approaches are under investigation. In NSCLC, mutations of HER-2 are found in 2%–4% of cases. The most commonly encountered mutations are frame insertions in exon 20. There is no evident association between HER-2 amplification and HER-2 mutations. HER-2-targeted therapy needs further clinical investigations in NSCLC.

Keywords:
HER-2 mutations, non-small cell lung cancer, HER-2 targeted therapy